A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
一项评估针对 PCSK9 的免疫疗法的安全性、耐受性、免疫原性和降低低密度脂蛋白胆固醇活性的 I 期研究
期刊:European Journal of Clinical Pharmacology
影响因子:2.4
doi:10.1007/s00228-021-03149-2
Markus Zeitlinger #, Martin Bauer #, Roman Reindl-Schwaighofer, Robert M Stoekenbroek, Gilles Lambert, Evelyn Berger-Sieczkowski, Heimo Lagler, Zoe Oesterreicher, Beatrix Wulkersdorfer, Petra Lührs, Gergana Galabova, Carsten Schwenke, Robert M Mader, Rossella Medori, Christine Landlinger, Alexandra